Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-07-16 Board/Management Inform…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Appointment of Richard Francis
Board/Management Information Classification · 95% confidence The document is an official announcement from Mereo BioPharma Group plc regarding the appointment of a new Head of Pharmaceutical Development. This falls under the category of senior management changes. While it is distributed via the RNS (Regulatory News Service), the content is specifically about a management appointment, making 'MANG' the most accurate classification.
2019-07-16 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by Mereo BioPharma Group plc, which is a report of a foreign private issuer submitted pursuant to SEC rules. The content primarily announces the appointment of a new Head of Pharmaceutical Development and provides company background and pipeline updates. There are no financial statements or detailed financial performance data included. The document is a regulatory announcement about management changes and company updates rather than a full financial report or earnings release. Given the focus on the appointment of a senior executive and company operational updates, the most appropriate classification is Board/Management Information (MANG). The document length (7387 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2019-07-16 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It reports a successful Type B meeting with the FDA and outlines an accelerated approval pathway for a drug candidate. The content is an announcement of a regulatory meeting outcome and clinical development update, not a full financial report or earnings release. The document length is 9234 characters, which is substantial but the content is primarily a corporate announcement about regulatory and clinical progress rather than detailed financial data or management discussion. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2019-07-15 English
Successful Type B Meeting with U.S. FDA
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Mereo BioPharma regarding a regulatory update (FDA Type B meeting) for a clinical trial. It is a standard corporate press release distributed via a regulatory news service, which falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or governance categories.
2019-07-15 English
6-K
Major Shareholding Notification Classification · 100% confidence The document is a Form 6-K filed by Mereo BioPharma Group plc, which is a report of a foreign private issuer pursuant to SEC rules. The content primarily details a notification of major holdings (TR-1 form) indicating changes in significant share ownership percentages by Woodford Investment Management Ltd. The document includes regulatory references, dates of notification, and voting rights percentages. It does not contain financial statements, management discussion, or detailed financial results. It is a regulatory filing notifying about a major shareholding change, consistent with the definition of Major Shareholding Notification (MRQ). The document length is 6287 characters, which is sufficient to contain substantive content, not just an announcement of a report. Therefore, the appropriate classification is MRQ.
2019-07-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Mereo BioPharma Group plc. It details a change in voting rights held by Woodford Investment Management Ltd, crossing a specific threshold. This is a classic 'Major Shareholding Notification' (TR-1 form), which corresponds to the MRQ filing category.
2019-07-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.